Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
Dabrafenib plus trametinib bij BRAF-V600E-gemuteerde zeldzame tumoren
jun 2023 | Hoofd-halsoncologie, Leukemie, Maag-darm-leveroncologie, MM, Neuro-oncologie